Emicizumab
- Generic Name
- Emicizumab
- Brand Names
- Hemlibra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1610943-06-0
- Unique Ingredient Identifier
- 7NL2E3F6K3
- Background
Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous ...
- Indication
The main function of Emicizumab is the prevention of bleeding episodes. Thus, Emicizumab is approved for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes of adult and pediatric patients with hemophilia A with or without Factor VIII inhibitors.
...
- Associated Conditions
- Bleeding caused by Hemophilia A
- Associated Therapies
- -
Next-Gen Hemophilia Treatments Offer Hope for Joint Health, but Accessibility Challenges Remain
HSSP Pharmacists Demonstrate Substantial Cost Avoidance in Specialty Medication Use
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.